Cartesian Therapeutics (RNAC) Change in Receivables (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Change in Receivables of -$854000.0 for Q1 2026, down 195.63% year-over-year from $893000.0 in Q1 2025, and down 317.3% quarter-over-quarter from $393000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Change in Receivables (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Change in Receivables for 12 consecutive years, with -$854000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 195.63% year-over-year to -$854000.0; the TTM figure through Mar 2026 stood at -$1.5 million (down 524.07% YoY), while the FY2025 annual figure was $243000.0, up 104.86% from the prior year.
- Change in Receivables eased to -$854000.0 in Q1 2026 per RNAC's latest filing, from $393000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $30.0 million in Q2 2024 and bottomed at -$27.2 million in Q3 2024.
- Historically, Change in Receivables has averaged -$567823.5 across 5 years, with a median of -$487000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 13591.87% — and 2024, when it plunged 5487.27%.
- Cartesian Therapeutics' Change in Receivables stood at -$329000.0 in 2022, then surged by 395.44% to $972000.0 in 2023, then sank by 507.1% to -$4.0 million in 2024, then surged by 109.93% to $393000.0 in 2025, then sank by 317.3% to -$854000.0 in 2026.
- Business Quant data shows RNAC's Change in Receivables at -$854000.0 in Q1 2026, $393000.0 in Q4 2025, and $368000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | -65,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -65,000.00 |
| Mar 31, 2026 | -854,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | 893,000.00 |
| Dec 31, 2024 | -3.96 Mn |
| Sep 30, 2024 | -27.21 Mn |
| Jun 30, 2024 | 30.03 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 972,000.00 |
| Sep 30, 2023 | -487,000.00 |
| Jun 30, 2023 | -1.45 Mn |
| Mar 31, 2023 | 243,000.00 |
| Dec 31, 2022 | -329,000.00 |
| Sep 30, 2022 | -17.07 Mn |
| Jun 30, 2022 | 16.84 Mn |
| Mar 31, 2022 | -2.76 Mn |
| Dec 31, 2021 | 2.59 Mn |
| Sep 30, 2021 | -1.14 Mn |